Tag: #immunotherapy

NICHE‑2 phase 2 follow‑up: short‑course neoadjuvant immunotherapy linked to 100% 3‑year disease‑free survival in dMMR colon cancer

NICHE‑2 reports 100% 3‑year disease‑free survival after brief neoadjuvant ipilimumab+nivolumab for dMMR colon cancer; single‑arm results need confirmation.

#immunotherapy, #colon-cancer, #clinical-trial, #dmmr

FDA Grants Accelerated Approval for GSK’s Jemperli in Biomarker-Defined Locally Advanced Rectal Cancer

FDA grants accelerated approval to GSK’s Jemperli for adults with stage II–III dMMR/MSI‑H locally advanced rectal cancer, potentially avoiding surgery.

$GSK, #health, #cancer, #fda, #immunotherapy

FDA Expands Use of Anktiva to Treat High-Grade Papillary Non‑Muscle Invasive Bladder Cancer

FDA expands Anktiva's approved use to adults with BCG‑unresponsive, high‑grade papillary-only non‑muscle invasive bladder cancer, providing a bladder‑sparing option.

#fda, #bladdercancer, #immunotherapy, #immunitybio

Durvalumab Plus FLOT Boosts Survival in Resectable Gastric and GEJ Cancer, MATTERHORN Shows

Phase 3 MATTERHORN shows AstraZeneca’s durvalumab added to perioperative FLOT improves overall and event‑free survival in resectable gastric/GEJ cancer.

$AZN, #oncology, #immunotherapy, #durvalumab, #gastric-cancer, #astrazeneca

NHS England rolls out 60-second pembrolizumab injection to cut treatment chair time

NHS England is introducing a subcutaneous form of pembrolizumab (Keytruda) that can be given in about a minute, reducing clinic time for roughly 14,000 patients.

#nhs, #pembrolizumab, #cancer, #immunotherapy

Study: dual‑target off‑the‑shelf CAR‑T cells resist rejection, curb tumor escape in mice

Nature Communications study finds donor 'off‑the‑shelf' CAR‑T cells targeting CD19 and CD70 persist longer and better control tumors in preclinical models.

$ALLO, #car-t, #immunotherapy, #allogeneic, #cd70